氯氮平在美国的应用现状(英文)

作     者：Deanna L.KELLY Heidi J.WEHRING Gopal VYAS 

作者机构：Maryland Psychiatric Research CenterUniversity of Maryland School of Medicine 

出 版 物：《上海精神医学》 (Shanghai Archives of Psychiatry)

年 卷 期：2012年第24卷第2期

页      面：110-113页

学科分类：1007[医学-药学(可授医学、理学学位)] 1006[医学-中西医结合] 100706[医学-药理学] 100602[医学-中西医结合临床] 10[医学] 

主　　题：氯氮平 美国 精神分裂症 精神病 药物 FDA 管理局 第二代 

摘      要：Clozapine is the only antipsychotic in the United States that has been approved by the Food and Drug Administration (FDA) for treatment-resistant schizophrenia. It provides effective treatment even when patients do not respond to other second- generation antipsychotics.[1] It also remains the most effective antipsychotic available. No existing first or second-generation antipsychotic has been